| Symbol | LGVN |
|---|---|
| Name | LONGEVERON INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1951 NW 7TH AVENUE,SUITE 520, MIAMI, Florida, 33136, United States |
| Telephone | +1 305 909-0840 |
| Fax | — |
| — | |
| Website | https://www.longeveron.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001721484 |
| Description | Longeveron Inc is a biotechnology company developing cellular therapies for specific ageing-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimers disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and Hypoplastic left heart syndrome (HLHS). Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Longeveron Inc. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001213900-26-088831 <b>Size:</b> 11 KB
Read moreLongeveron - Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
Read moreLongeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
Read moreLongeveron - Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition
Read moreLongeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition
Read moreNew Form SCHEDULE 13G - Longeveron Inc. <b>Filed:</b> 2026-08-10 <b>AccNo:</b> 0001104659-26-093455 <b>Size:</b> 18 KB
Read moreLongeveron - Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026
Read moreLongeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026
Read moreLongeveron - Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT02587572 | Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SI… | Phase2 | Metabolic Disease | Withdrawn | 2023-12-01 | 2023-12-01 | ClinicalTrials.gov |
| NCT05233774 | Lomecel-B Effects on Alzheimer's Disease | Phase2 | Mild Alzheimer's Disease | Completed | 2021-12-28 | 2023-09-29 | ClinicalTrials.gov |
| NCT04925024 | Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Synd… | Phase2 | Hypoplastic Left Heart Syndrome | Active_Not_Recruiting | 2021-06-25 | 2026-08-31 | ClinicalTrials.gov |
| NCT04629105 | Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOV… | Phase1 | ARDS, Human | Unknown | 2020-07-24 | 2025-07-01 | ClinicalTrials.gov |
| NCT03525418 | Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome… | Phase1 | HLHS | Unknown | 2018-02-21 | 2025-12-31 | ClinicalTrials.gov |
| NCT03169231 | Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Fr… | Phase2 | Aging Frailty | Completed | 2017-07-06 | 2021-09-30 | ClinicalTrials.gov |
| NCT02982915 | Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty | Phase1 | Aging Frailty | Completed | 2016-11-01 | 2022-09-01 | ClinicalTrials.gov |
| NCT02600130 | Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease | Phase1 | Alzheimer's Disease | Completed | 2016-10-10 | 2021-09-01 | ClinicalTrials.gov |
| NCT02398604 | Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome | Phase1 | Hypoplastic Left Heart Syndrome | Terminated | 2015-04-01 | 2019-03-01 | ClinicalTrials.gov |
| NCT02065245 | AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy V… | Phase1 | Frailty | Completed | 2014-03-03 | 2020-10-02 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) | Other | Phase PHASE1 | Frailty | COMPLETED | NCT02065245 |
| Placebo | Other | Phase PHASE1 | Frailty | COMPLETED | NCT02065245 |
| Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) | Other | Phase PHASE1 | Frailty | COMPLETED | NCT02065245 |
| Placebo | Other | Phase PHASE1 | Hypoplastic Left Heart Syndrome | TERMINATED | NCT02398604 |
| Allo-hMSCs | Other | Phase PHASE1 | Hypoplastic Left Heart Syndrome | TERMINATED | NCT02398604 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02600130 |
| Longeveron Mesenchymal Stem Cells | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02600130 |
| Placebo | Other | Phase PHASE2 | Aging Frailty | COMPLETED | NCT03169231 |
| Longeveron Mesenchymal Stem Cells (LMSCs) | Other | Phase PHASE2 | Aging Frailty | COMPLETED | NCT03169231 |
| Fluzone High Dose Vaccine | Other | Phase PHASE1 | Aging Frailty | COMPLETED | NCT02982915 |
| Longeveron Mesenchymal Stem Cells (LMSCs) | Other | Phase PHASE1 | Aging Frailty | COMPLETED | NCT02982915 |
| Peripheral Intravenous (IV) infusion of LMSCs | Other | Phase PHASE2 | Metabolic Disease | WITHDRAWN | NCT02587572 |
| Longeveron Mesenchymal Stem Cells | Other | Phase PHASE1 | HLHS | UNKNOWN | NCT03525418 |
| Placebo | Other | Phase PHASE2 | Mild Alzheimer's Disease | COMPLETED | NCT05233774 |
| Allogeneic MSC | Other | Phase PHASE2 | Mild Alzheimer's Disease | COMPLETED | NCT05233774 |
| Placebo | Other | Phase PHASE1 | ARDS, Human | UNKNOWN | NCT04629105 |
| Longeveron Mesenchymal Stem Cells (LMSCs) | Other | Phase PHASE1 | ARDS, Human | UNKNOWN | NCT04629105 |
| Lomecel-B medicinal signaling cells | Other | Phase PHASE2 | Hypoplastic Left Heart Syndrome | ACTIVE_NOT_RECRUITING | NCT04925024 |
| Allogeneic MSC | DRUG | Phase PHASE2 | Mild Alzheimer's Disease | COMPLETED | NCT05233774 |
| Lomecel-B medicinal signaling cells | BIOLOGICAL | Phase PHASE2 | Hypoplastic Left Heart Syndrome | ACTIVE_NOT_RECRUITING | NCT04925024 |
| Fluzone High Dose Vaccine | BIOLOGICAL | Phase PHASE1 | Aging Frailty | COMPLETED | NCT02982915 |
| Longeveron Mesenchymal Stem Cells (LMSCs) | BIOLOGICAL | Phase PHASE1 | ARDS, Human | ACTIVE_NOT_RECRUITING | NCT04629105 |
| Longeveron Mesenchymal Stem Cells | BIOLOGICAL | Phase PHASE1 | HLHS | ACTIVE_NOT_RECRUITING | NCT03525418 |
| Peripheral Intravenous (IV) infusion of LMSCs | BIOLOGICAL | Phase PHASE2 | Metabolic Disease | WITHDRAWN | NCT02587572 |
| Allo-hMSCs | DRUG | Phase PHASE1 | Hypoplastic Left Heart Syndrome | TERMINATED | NCT02398604 |
| Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) | BIOLOGICAL | Phase PHASE1 | Frailty | COMPLETED | NCT02065245 |
| Placebo | OTHER | Phase PHASE2 | Mild Alzheimer's Disease | COMPLETED | NCT05233774 |
| Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) | BIOLOGICAL | Phase PHASE1 | Frailty | COMPLETED | NCT02065245 |